EMVision Medical Devices (ASX: EMV) is expanding its pivotal FDA De Novo trial to include acute ischaemia detection, a move intended to broaden the potential indications for its emu device and streamline the regulatory pathway.
This expansion leverages existing trial infrastructure and patient cohorts, with the company expecting trial modifications to be modest and incremental.
The addition is designed to broaden potential indications from the initial FDA De Novo clearance, which primarily targets haemorrhage detection.
The primary objective for haemorrhage detection remains a sensitivity and specificity of >80%.
Pivotal Trial Progress and Funding
Pivotal trial recruitment has surpassed 125 patients with no device-related adverse events reported to date.
Full enrolment is anticipated by late 2026/early 2027, with sequential cohort readouts to follow shortly thereafter.
The company holds AUD 18.4 million in cash reserves as of March 31, 2026.
A further AUD 0.4 million non-dilutive payment was received in May 2026 from CRC-P funding, supporting continued trial execution and commercialisation milestones.
Regional Benefit Study Advancements
Progress is being made on the em Regional Benefit Study, which is funded by CRC-P.
Site selection is well advanced, with ethics approval anticipated in H2 2026.
This study aims to demonstrate accelerated stroke diagnosis and management, particularly for underserved regional patients via telehealth.
Adding the ischaemia endpoint introduces regulatory and execution uncertainty, with performance for acute ischaemia detection considered more complex than haemorrhage detection.
No performance results for acute ischaemia detection have been reported yet.
EMVision's Strategic Trial Expansion
EMVision's decision to add an acute ischaemia detection endpoint to its pivotal FDA trial represents a strategic move to potentially accelerate regulatory approval and expand the market potential of its emu device.
While this expansion carries inherent execution and regulatory risks related to the new endpoint, the continued progress in patient recruitment and the company's solid funding position provide a supportive backdrop for this development.
Successful validation of this new endpoint is critical for the expanded regulatory claim.
